Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.

Adjuvant treatment with tamoxifen. Recruitment into studies assessing optimum duration of treatment must continue.

Bibliographic Details
Main Authors:	Earl, H, Baker, P, Kerr, D, Lee, M, Gray, R, Baum, M
Format:	Journal article
Language:	English
Published:	1996

Similar Items

[Duration of adjuvant treatment with tamoxifen in patients with resectable breast cancer]
by: Davies, C, et al.
Published: (1998)

[Adjuvant tamoxifen duration: more large-scale randomized evidence is needed]
by: Davies, C, et al.
Published: (1997)

Variation in use of adjuvant tamoxifen.
by: Davies, C, et al.
Published: (1998)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
by: Stefan A. J. Buck, et al.
Published: (2022-03-01)

The endometrium in women receiving adjuvant tamoxifen therapy after surgical treatment of breast cance
by: E V Dmitrieva, et al.
Published: (2013-12-01)

Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
by: Gelber, R, et al.
Published: (1996)

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
by: Dowsett, M, et al.
Published: (2009)

Tamoxifen treatment adherence assessment by women with breast cancer
by: Caroline Oliveira Rangel, et al.
Published: (2020-01-01)

Adjuvant CMF and tamoxifen in the elderly breast cancer patients
by: Vrbavac Milenko, et al.
Published: (2002-01-01)

Ovarian hyperstimulation syndrome followed by ovarian torsion in premenopausal patient using adjuvant tamoxifen treatment for breast cancer
by: Behnaz Moradi, et al.
Published: (2016-09-01)

Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer
by: Rea, D, et al.
Published: (2013)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
by: Martinez-Cannon BA, et al.
Published: (2021-05-01)

Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen.
by: Davies, C
Published: (2004)

Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
by: Abahssain Halima, et al.
Published: (2010-08-01)

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer
by: Early Breast Cancer Trialists' Collaborative Group
Published: (1988)

Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer
by: Jaime D. Lewis, et al.
Published: (2014-11-01)

Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.
by: Mustafa Al-Mubarak, et al.
Published: (2014-01-01)

The use of tamoxifen in the treatment and prevention of breast cancer
by: Magdalena Hołowczuk, et al.
Published: (2019-06-01)

The use of tamoxifen in the treatment and prevention of breast cancer
by: Magdalena Hołowczuk, et al.
Published: (2019-06-01)

Risk of Parkinson's disease after tamoxifen treatment
by: Destefano Anita L, et al.
Published: (2010-04-01)

Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea
by: Dooreh Kim, et al.
Published: (2023-02-01)

Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
by: Ana D. Pinzón-García, et al.
Published: (2021-10-01)

Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
by: Sara Alkner, et al.
Published: (2016-01-01)

Effects of chronic tamoxifen treatment in female rat sexual behaviour
by: Cláudia A. Pinto, et al.
Published: (2022-12-01)

Research progress in tamoxifen in treatment of encapsulating peritoneal sclerosis
by: Kang Daxian, Sun Liping, Zhang Xinzhou
Published: (2024-01-01)

Tamoxifen Treatment for Riedel’s Thyroiditis: A Case Report
by: Ersen Karakılıç, et al.
Published: (2023-10-01)

Behavioral and transcriptomic effects of the cancer treatment tamoxifen in mice
by: Elena Galvano, et al.
Published: (2023-02-01)

The Use of Tamoxifen as a Potential Treatment for Bipolar Disorder
by: Noy Bagdadi, et al.
Published: (2021-09-01)

Tamoxifen is effective in the treatment of Leishmania amazonensis infections in mice.
by: Danilo C Miguel, et al.
Published: (2008-01-01)

New approaches for the treatment of colorectal cancer in the adjuvant setting
by: Kerr, D, et al.
Published: (2004)

Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF−7/SC Breast Cancer Cells
by: Ngoc Bao To, et al.
Published: (2022-09-01)

Adjuvant chemotherapy for colorectal cancer.
by: Kerr, D, et al.
Published: (1996)

10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS
by: Davies, C, et al.
Published: (2017)

Evaluation of Saline Sonohysterography Findings in Patients with Breast Cancer Receiving Tamoxifen Adjuvant Therapy
by: Maryam Rahmani, et al.
Published: (2016-12-01)

Tamoxifen in breast conservation therapy.
by: Lee, K, et al.
Published: (1995)

Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
by: Emily K. Zboril, et al.
Published: (2023-06-01)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
by: Lundgren Steinar, et al.
Published: (2010-06-01)

Fructose and cardiometabolic disorders: the controversy will, and must, continue
by: Nicolas Wiernsperger, et al.
Published: (2010-01-01)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.
by: Davies, C, et al.
Published: (2013)

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
by: Davies, C, et al.
Published: (2013)